A new drug, yet to be approved by the Therapeutic Goods Administration, is giving a small group of chronic Cystic Fibrosis (CF) patients at Mater a second chance at life.
A new triple-combination drug trialled at Mater in Brisbane could increase the life expectancy of patients with cystic fibrosis (CF).